♟️ Wednesday 28 October 2026 Wed, 28 Oct 2026

MB Gold has finished its latest Marble Bar drilling campaign with assays pending, while a geophysical survey has opened several deeper targets across the project. The explorer ended September with $4.84 million in cash after spending $1.19 million on exploration during the quarter.

Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.

PolarX has reported exceptional copper assays from its 2026 Caribou Dome drilling, including 24.8 metres at 9.8% copper and a 58.5-metre interval extending mineralisation beyond the existing resource. The results strengthen the exploration case, but the company ended September with A$4.04 million in cash and 0.71 quarters of funding on its reported spending rate.

Elixir Energy has told ASX that its $205 million strategic farm-out with Beach Energy was material price-sensitive information and became disclosable when documents were signed. The company says it released the deal before trading resumed and remained compliant with continuous disclosure rules.

The Australian Takeovers Panel has declared unacceptable circumstances in A2MP Investments’ lapsed A$0.05-a-share takeover bid for Canyon Resources, citing inadequate disclosure, the use of confidential information and potential coercion of shareholders. Final orders remain undecided.

Tarrina Resources has expanded the exploration case for both its NSW gold project and South Australian copper-gold project, with six Christmas Gift holes intersecting gold and Walparuta work defining 23 drill targets. The company ended the quarter with $1.72 million in cash, but Walparuta drilling remains dependent on approvals and native title negotiations.

Antimony Resources has moved its Tecomatlán plant into its first plant-scale antimony concentrate campaign, but reported only 0.9 quarters of funding at September’s cash burn. The campaign could provide the company’s first operating proof point, while also sharpening the need for additional financing or commercial revenue.

Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.

Bindi Metals has expanded its key Drenjak gold intersection in Serbia to 8 metres at 13.1 g/t gold, while identifying further silver and nickel-cobalt targets at Ravni. The exploration progress comes with only A$459,000 in cash and a stated 0.38 quarters of funding, putting the next drilling phase behind a potential capital raising.

Iris Cairns Property has lifted its relevant interest in Reef Casino Trust to 96.50%, crossing the threshold needed to compulsorily acquire the remaining units at $4.67 each. The offer closes on 9 November and Iris says it will not be extended unless required by law.

Peppermint Innovation’s Philippine payments business delivered a sharp September-quarter acceleration, with customer receipts rising to A$1.18 million and operating cash outflow falling 55%. The company says early October volumes have already exceeded September’s full-month total, while ASX reinstatement remains conditional.

High-Tech Metals has entered the December quarter with a 47% increase in the Mt Fisher Mineral Resource, $8.9 million in cash and a Wagtail development study approaching completion. The company now faces the harder test of converting resource growth into a credible production pathway.

Elsight delivered US$25.8 million in unaudited revenue for the first nine months of 2026, up 91% on the prior corresponding period, but a weaker-than-expected third quarter produced a non-GAAP loss. The company is relying on expanded US defence procurement access, new products and a US$196 million opportunity pipeline to support future growth.

Innovaero Technologies has reported a $5.917 million FY2026 loss as it prepares to scale OWL drone production after its ASX debut and $40 million capital raise. The annual report shows a better-funded business, but one still reliant on government contracts, certification and forecast production work.

Octava Minerals is pursuing a staged Argentine fluorspar option while its auditor flags material uncertainty over the explorer’s ability to continue as a going concern. The company ended September with A$322,000 in cash and is relying on shareholder-backed funding to advance both the new project and its Byro critical minerals target.

Australia United Mining generated a $20,803 share of gold and silver proceeds from its Ropewalk operation, but ended September with only about $20,000 in cash. The company says it may sell a listed investment and rely on related-party support to meet its commitments.

Energy World has received US$60 million directly from Hallador Energy and secured a further US$265 million in escrow after delivering two gas turbines. The remaining payments depend on inspection, refurbishment and completion milestones expected by February 2027.

Matsa Resources has reported a $39.4 million FY2026 loss, negative net assets and a $28 million operating cash outflow after Devon operated at a loss and was suspended following a contractor dispute. A $55 million AngloGold tenement sale offers a potential liquidity reset, but the annual report says material uncertainty remains over the group's ability to continue as a going concern.

PARKD’s FY26 annual report puts the company’s funding position under sharper scrutiny after a steep revenue decline, a $1.26 million loss and $367,714 in cash. Its east-coast expansion produced new facilities, partnerships and demonstrations, but the next test is converting that platform into contracted work quickly enough.

PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.

Chilwa Minerals has expanded its Chilwa project’s heavy mineral sands resource by 56% and added niobium and rare earths to the story. But the annual report also records a larger loss, limited year-end cash and an auditor warning over going concern, despite a subsequent US$3.5 million Nasdaq raising.

Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.

Tinybeans has delivered a US$65,000 adjusted EBITDA profit and its fourth consecutive quarter of positive operating cash flow, with revenue rising 35% to US$1.60 million. The result came as subscription revenue climbed 74%, although customer acquisition costs increased across both platforms.

Reward Minerals has completed its maiden drilling program at the Jackpot gold-copper prospect, but the more immediate investor issue is funding: the company held $262,000 in cash at 30 September, equivalent to 0.43 quarters of reported outgoings. Reward says it intends to pursue a placement or entitlement issue while awaiting assay results and continuing Beyondie partnership talks.